Driven by Expertise
We are pioneers in developing a quantitative test to track a clinical marker - the muscle pressure in the trapezius muscle.
Envisioning to be a collaborator for pharmaceutical companies to develop treatment plans and drugs aided by the proprietary data we collect in accordance with the clinical marker.
We plan to develop the test that provides a objective diagnosis for the over 10 million people afflicted with fibromyalgia
Our Product
The patented device will read the muscle pressure using our proprietary algorithm to provide accurate instant readout of diagnosis. The device will be packaged to be easily sterilized and maintained in regards
to needle and saline injections required for measuring muscle pressure in a patient's trapezius.
The revenue plan consists of supplying a consumable product that provides an easy to use digital readout. By providing a disposable element, we lessen the burden of maintenance and sterilization from the doctor’s office while providing a recurring source of revenue.
Cutting-Edge Research
Our team will be presenting multiple papers at the upcoming American College of Rheumatology (ACR) Convergence 2024. Continuing reading below for information regarding our most recent research on fibromyalgia.
Association Between Fibromyalgia and Serum Levels of Calcitonin Gene-Related Peptide and Vascular Endothelial Growth Factor: A Meta-Analysis
Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup
Fibromyalgia’s Under-Representation in Rheumatology Literature: A Ten-Year Analysis of Disease-Specific Article Distribution
Fibromyalgia involves muscle pain, fatigue, and cognitive issues, but its diagnosis is challenging due to a lack of reliable blood markers. This review and meta-analysis examined serum levels of peptides in patients. Results showed significantly higher of specific peptides in patients compared to controls, suggesting further diagnostic measures for fibromyalgia.
Fibromyalgia patients face challenges in proving eligibility for Social Security Disability Insurance (SSD) due to the need for specific signs and functional impairments. A study found that 30.12% of FM patients received SSD, compared to over 50% for those with rheumatoid arthritis (RA) or osteoarthritis (OA). Functional status was a key predictor of SSD approval.
Fibromyalgia affects up to 12 million U.S. adults but is under-researched compared to other rheumatologic diseases. A review of major journals (2014-2024) found significantly fewer fibromyalgia articles compared to other conditions like rheumatoid arthritis. This highlights a need for more research into fibromyalgia and suggests potential publication bias
12 million Americans suffer from Fibromyalgia, but only know their symptoms as chronic pain. Many physicians are unaware or unable to provide a diagnosis of Fibromyalgia.